anastrozole — Aromatase inhibitor (AI) — non-steroidal

Competitively inhibits aromatase enzyme (CYP19A1), blocking conversion of androgens (testosterone, androstenedione) to estrogens (estradiol, estrone). Reduces serum estradiol by ~70-80%.

Overview

This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.

Compound Class

Aromatase inhibitor (AI) — non-steroidal

Mechanism of Action

Competitively inhibits aromatase enzyme (CYP19A1), blocking conversion of androgens (testosterone, androstenedione) to estrogens (estradiol, estrone). Reduces serum estradiol by ~70-80%.

Regulatory Status

FDA approved (breast cancer)

Evidence Level

High — FDA-approved; extensive oncology data; well-studied in TRT context